eik1001
eik1001: sourced relationships with 1 company · 3 clinical trials tracked.
eik1001 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could eik1001 → EIKN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Eikon Therapeutics Inc. (EIKN) NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamo… | Phase 2/Phase 3 |
Clinical Trial Registry Records (3)
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
Primary endpoint: Progression-free survival (PFS)
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)
Primary endpoint: Progression Free Survival (PFS)
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
Primary endpoint: Percentage of participants with safety event during treatment
Frequently asked questions
Which companies have sourced relationships with eik1001?
eik1001 has dated SEC/FDA relationship records for Eikon Therapeutics Inc..
How many clinical trials involve eik1001?
BioSniper tracks 3 clinical trials involving eik1001.